Etanercept for treating SAPHO syndrome
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study tests if etanercept, a biologic drug that targets inflammation, safely reduces pain and disease activity in people with SAPHO syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of SAPHO syndrome.
- You must be at least 18 years old.
- You must have a pain and overall disease severity score of 4 or higher on a 10-point scale.
- You cannot be pregnant, breastfeeding, or unwilling to use effective birth control during the study.
- You must not have changed your NSAID dose in the past 4 weeks, or your DMARD dose in the past 12 weeks.
- You must not have taken any biologic or targeted synthetic drug in the past 12 weeks, or corticosteroids, bisphosphonates, or antibiotics in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the causes of SAPHO syndrome—a rare condition that affects the skin, bones, and joints. Researchers want to understand how genes and the immune system play a role, which may help improve future treatments.
This trial tests whether adding a common antibiotic (benzathine penicillin) to a standard biologic drug (etanercept) can better treat spondyloarthritis. It may help if you have active disease and are free of certain infections.
This study tests if guselkumab can reduce pain and inflammation in people with psoriatic arthritis. You may join if standard treatments have not worked well enough or caused side effects.
This study looks at a specific enzyme (15-hydroxyprostaglandin dehydrogenase) in people with osteoarthritis or ankylosing spondylitis. It may help researchers understand these conditions better and find new treatment targets.
This trial studies whether adding a biologic medicine (targeted therapy) can help people with active spondyloarthritis when standard anti-inflammatory pain medicines (NSAIDs) have not worked well enough. It focuses on people with ongoing symptoms despite trying at least two NSAIDs.
This trial studies advanced medicines for rheumatoid arthritis (RA) in people whose RA is still active despite several standard treatments. It may help by testing whether a different advanced option can better control symptoms and joint inflammation.
Hear when a new SAPHO Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.